- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.05. | MSD concludes Terns acquisition to expand CML pipeline | ||
| 05.05. | Madrigal outlays $1bn for Arrowhead's siRNA MASH asset | ||
| 05.05. | UCB doubles down on TCEs with $2.2bn Candid buyout | ||
| 05.05. | Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara | ||
| 05.05. | Latus Bio secures $97m in funding to boost gene therapy access | ||
| 04.05. | Arrowhead's Redemplo secures Australian TGA approval for FCS therapy | ||
| 04.05. | Novo Nordisk to launch Ozempic for type 2 diabetes in US | ||
| 01.05. | Axsome receives FDA approval for Auvelity to treat Alzheimer's agitation | ||
| 01.05. | Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening | ||
| 01.05. | BMS brings the buzz around late-stage readouts amid a so-so Q1 | ||
| 01.05. | LEO Pharma to acquire gene therapy company Replay | ||
| 30.04. | Chiesi widens rare disease portfolio with $1.9bn KalVista buyout | ||
| 30.04. | Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy | ||
| 30.04. | Ray Therapeutics receives EMA PRIME status for gene therapy | ||
| 30.04. | Regeneron Q1 2026 net income falls 10% to $727m | ||
| 29.04. | Pfizer protects $6.4bn heart disease blockbuster from generics, for now | ||
| 29.04. | Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact | ||
| 29.04. | Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies | ||
| 29.04. | Arcera and Fosun sign MoU for neuroscience innovation | ||
| 29.04. | Rocket to sell PRV for $180m to advance gene therapy pipeline | ||
| 28.04. | Merck KGaA and Remepy join forces to develop combo drug-digital therapies | ||
| 28.04. | Seaport Therapeutics and Hemab target $180m IPOs as biotech listings accumulate | ||
| 28.04. | BioMarin acquires Amicus Therapeutics for $4.8bn | ||
| 28.04. | FDA approves AstraZeneca's Saphnelo for SLE | ||
| 27.04. | Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.